Autolus Therapeutics plc American Depositary Share (AUTL) Stock Price

AUTLStock

$2.44+33.71%52W

Market Cap$649.44M

P/E—

PEG Ratio—

Div yield—

Beta2.15

AUTL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)38.75%

Price vs S&P 500 (4W)58.33%

VGM Score68.75

Book Value / Share (Quarterly)$1.30

P/TBV (Annual)3.31x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)128.01%

Price vs S&P 500 (YTD)5.63%

Gross Margin (TTM)18.30%

Net Profit Margin (TTM)-238.66%

EPS (TTM)$-1.05

10-Day Avg Trading Volume3.75M

EPS Excl Extra (TTM)$-1.05

Revenue Growth (5Y)112.99%

EPS (Annual)$-1.08

ROI (Annual)-64.13%

Gross Margin (Annual)-26.10%

Net Profit Margin (5Y Avg)-4654.61%

Cash / Share (Quarterly)$1.71

Revenue Growth QoQ (YoY)118.37%

ROA (Last FY)-48.81%

Revenue Growth TTM (YoY)292.16%

EBITD / Share (TTM)$-0.90

ROE (5Y Avg)-99.04%

Operating Margin (TTM)-210.78%

Cash Flow / Share (Annual)$-0.30

P/B Ratio8.57x

P/B Ratio (Quarterly)5.69x

Net Income / Employee (Annual)$-381,300

EV / Revenue (TTM)6.32x

Net Interest Coverage (TTM)-17.39x

ROA (TTM)-49.34%

EPS Incl Extra (Annual)$-1.08

Current Ratio (Annual)5.94x

Quick Ratio (Quarterly)4.12x

3-Month Avg Trading Volume1.81M

52-Week Price Return33.71%

Revenue / Employee (TTM)$155,700

Tangible BV / Share (Quarterly)$1.25

P/S Ratio (Annual)8.51x

Asset Turnover (Annual)0.13x

52-Week High$2.58

Operating Margin (5Y Avg)-4610.29%

EPS Excl Extra (Annual)$-1.08

CapEx CAGR (5Y)13.07%

Tangible BV CAGR (5Y)-9.06%

26-Week Price Return50.00%

Quick Ratio (Annual)5.19x

13-Week Price Return41.82%

Total Debt / Equity (Annual)1.52x

Current Ratio (Quarterly)4.89x

Enterprise Value$741.42M

Revenue / Share Growth (5Y)53.36%

Asset Turnover (TTM)0.21x

Revenue / Employee (Annual)$100,000

Pretax Margin (Annual)-378.78%

Cash / Share (Annual)$3.53

3-Month Return Std Dev83.62%

Net Income / Employee (TTM)$-371,600

ROE (Last FY)-161.42%

Net Interest Coverage (Annual)-5.41x

EPS Basic Excl Extra (Annual)$-1.08

Receivables Turnover (TTM)3.19x

Total Debt / Equity (Quarterly)3.63x

EPS Incl Extra (TTM)$-1.05

Receivables Turnover (Annual)5.49x

ROI (TTM)-65.71%

P/S Ratio (TTM)5.46x

Pretax Margin (5Y Avg)-4933.00%

Revenue / Share (Annual)$0.28

Price vs S&P 500 (52W)15.40%

Year-to-Date Return17.59%

5-Day Price Return2.18%

EPS Normalized (Annual)$-1.08

ROA (5Y Avg)-39.58%

Net Profit Margin (Annual)-381.40%

Month-to-Date Return57.05%

Cash Flow / Share (TTM)$-0.97

EBITD / Share (Annual)$-0.99

Operating Margin (Annual)-358.87%

LT Debt / Equity (Annual)1.52x

ROI (5Y Avg)-53.19%

LT Debt / Equity (Quarterly)3.63x

EPS Basic Excl Extra (TTM)$-1.05

P/TBV (Quarterly)7.56x

P/B Ratio (Annual)2.94x

Inventory Turnover (TTM)3.34x

Pretax Margin (TTM)-238.08%

Price vs S&P 500 (13W)39.02%

Beta2.15x

Revenue / Share (TTM)$0.44

ROE (TTM)-178.66%

52-Week Low$1.18

vGradeC

gGradeA

mGradeB

vgmGradeB

AUTL Earnings Surprise History

Q2 25-0.18est. -0.24

Q3 25-0.30est. -0.23

Q4 25-0.34est. -0.27

Q1 26-0.27est. -0.26

Q2 26-0.15est. -0.19

AUTL Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.28

4.29

4.31

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
AUTLAutolus Therapeutics plc American Depositary Share	C	A	B	$2.44
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Autolus Therapeutics plc American Depositary Share

Autolus Therapeutics develops next-generation programmed T-cell therapies for cancer treatment. The biopharmaceutical company's clinical-stage pipeline is anchored by Obe-cel and includes several additional programs (AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7, and AUTO8) at varying developmental stages.